|
|
Article: Ciprofloxacin GR trial among highlights of company's second quarter.
- Article from:
- Clinical Trials Week
- Article date:
- September 8, 2003
CopyrightCOPYRIGHT 2003 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Depomed, Inc., (DMI) announced a net loss of $7,168,000, or $0.30 per share, for the quarter ended June 30, 2003, compared to a net loss of $7,000,000, or $0.50 per share, for the quarter ended June 30, 2002.
Cash and investment balances at June 30, 2003, were approximately $22,434,000.
"Depomed achieved a number of important corporate and product development milestones this quarter, including the completion of a $20 million private placement, the certification of our laboratories and manufacturing facilities, and the initiation of a pivotal phase III clinical trial with our once daily antibiotic Ciprofloxacin GR ...